Literature DB >> 8105027

Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine.

M Kalian1, V Lerner, M Goldman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105027     DOI: 10.1097/00005053-199310000-00014

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


× No keyword cloud information.
  7 in total

1.  Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study.

Authors:  Itzhak Kimiagar; Evgenia Dobronevsky; Tatiana Prokhorov; Ala Miniovitz; Jose M Rabey
Journal:  J Neurol       Date:  2011-11-09       Impact factor: 4.849

Review 2.  Movement disorders: neurodevelopment and neurobehavioural expression.

Authors:  T Archer; R J Beninger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

Review 3.  Tourette syndrome: clinical characteristics and current management strategies.

Authors:  E H Kossoff; H S Singer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Treatment strategies for tics in Tourette syndrome.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-01       Impact factor: 6.570

Review 5.  A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.

Authors:  Jocelyn Wong; Tiffanie Pang; Natalie Kwok Wing Cheuk; Yingqi Liao; Tarun Bastiampillai; Sherry Kit Wa Chan
Journal:  Psychopharmacology (Berl)       Date:  2022-09-30       Impact factor: 4.415

Review 6.  The treatment of tics.

Authors:  H S Singer
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 6.030

7.  Update on the role of antipsychotics in the treatment of Tourette syndrome.

Authors:  Daniel Huys; Katja Hardenacke; Pia Poppe; Christina Bartsch; Burak Baskin; Jens Kuhn
Journal:  Neuropsychiatr Dis Treat       Date:  2012-03-12       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.